BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31165208)

  • 1. [Antisense therapies for neurological diseases].
    Pulst SM
    Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides: A primer.
    Scoles DR; Minikel EV; Pulst SM
    Neurol Genet; 2019 Apr; 5(2):e323. PubMed ID: 31119194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gene-specific treatment approaches in muscle diseases].
    Lehmann Urban D; Schneider I
    Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligonucleotide therapeutics in neurodegenerative diseases.
    Scoles DR; Pulst SM
    RNA Biol; 2018; 15(6):707-714. PubMed ID: 29560813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
    Li D; Mastaglia FL; Fletcher S; Wilton SD
    Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
    Holm A; Hansen SN; Klitgaard H; Kauppinen S
    RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASO Therapy: Hope for Genetic Neurological Diseases.
    Muth CC
    JAMA; 2018 Feb; 319(7):644-646. PubMed ID: 29383373
    [No Abstract]   [Full Text] [Related]  

  • 8. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
    Cantara S; Simoncelli G; Ricci C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense therapies in neurological diseases.
    Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
    Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
    Barresi V; Musmeci C; Rinaldi A; Condorelli DF
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense therapies for movement disorders.
    Scoles DR; Pulst SM
    Mov Disord; 2019 Aug; 34(8):1112-1119. PubMed ID: 31283857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
    Bennett CF; Krainer AR; Cleveland DW
    Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic antisense oligonucleotides for movement disorders.
    Doxakis E
    Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey.
    Oberemok VV; Laikova KV; Repetskaya AI; Kenyo IM; Gorlov MV; Kasich IN; Krasnodubets AM; Gal'chinsky NV; Fomochkina II; Zaitsev AS; Bekirova VV; Seidosmanova EE; Dydik KI; Meshcheryakova AO; Nazarov SA; Smagliy NN; Chelengerova EL; Kulanova AA; Deri K; Subbotkin MV; Useinov RZ; Shumskykh MN; Kubyshkin AV
    Molecules; 2018 May; 23(6):. PubMed ID: 29844255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational development of splice-modifying antisense oligomers.
    Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
    Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense Oligonucleotides for the Study and Treatment of ALS.
    Boros BD; Schoch KM; Kreple CJ; Miller TM
    Neurotherapeutics; 2022 Jul; 19(4):1145-1158. PubMed ID: 35653060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
    Touznik A; Lee JJ; Yokota T
    Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis.
    Ly CV; Miller TM
    Curr Opin Neurol; 2018 Oct; 31(5):648-654. PubMed ID: 30028737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.